Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer
Top Cited Papers
- 1 October 2007
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 6 (10) , 821-833
- https://doi.org/10.1038/nrd2359
Abstract
Insulin-like growth factor 1 (IGF1) is a polypeptide hormone that has a high degree of structural similarity to human proinsulin. Owing to its ubiquitous nature and its role in promoting cell growth, strategies to inhibit IGF1 actions are being pursued as potential adjunctive measures for treating diseases such as short stature, atherosclerosis and diabetes. In addition, most tumour cell types possess IGF1 receptors and conditions in the tumour microenvironment, such as hypoxia, can lead to enhanced responsiveness to IGF1. Therefore, inhibiting IGF1 action has been proposed as a specific mechanism for potentiating the effects of existing anticancer therapies or for directly inhibiting tumour cell growth.Keywords
This publication has 150 references indexed in Scilit:
- Insulin-like Growth Factor 1/Insulin Signaling Activates Androgen Signaling through Direct Interactions of Foxo1 with Androgen ReceptorJournal of Biological Chemistry, 2007
- Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailabilityBiochemical and Biophysical Research Communications, 2005
- Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cellsBiochemical and Biophysical Research Communications, 2005
- A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor ActivityJournal of Biological Chemistry, 2005
- Cytokine inhibition of JAK-STAT signaling: a new mechanism of growth hormone resistancePediatric Nephrology, 2004
- Proprotein convertases regulate insulin-like growth factor 1-induced membrane-type 1 matrix metalloproteinase in VSMCs via endoproteolytic activation of the insulin-like growth factor-1 receptorBiochemical and Biophysical Research Communications, 2004
- Dual Regulation of MMP-2 Expression by the Type 1 Insulin-like Growth Factor ReceptorJournal of Biological Chemistry, 2004
- Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signalingOncogene, 2003
- Circulating concentrations of insulin-like growth factor I and risk of breast cancerThe Lancet, 1998
- Mini-proinsulin and mini-IGF-I: homologous protein sequences encoding non-homologous structuresJournal of Molecular Biology, 1998